Blood platelets metabolic and activation processes and options for their inhibition

Czech version

Authors: M. Pecka; J. Malý
Authors‘ workplace: Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, a Katedra interních oborů Lékařské fakulty UK Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
Published in: Vnitř Lék 2009; 55(3): 263-266
Category: 15th Parizek's Days

Overview

A range of activation processes and confirmatory and metabolic changes take place in blood platelets following their activation. The paper discusses some of the blood platelet activation steps and describes the specific processes that take place on this level. Furthermore, the points at which it is possible to actively interfere with the blood platelet metabolism or activation processes are described. Antiplatelet treatment focuses on these points and there are efforts to identify active substances that either inhibit access to certain receptors or targets or, alternatively, inhibit the enzymes participating in these processes.

Key words:
blood platelet – activation – adhesion – aggregation – inhibition – blockade – antiplatelet treatment

Sources

1. Badimon L, Badimon JJ. Interaction of platelet activation and coagulation. In: Fuster V, Topol EJ (eds). Atherosclerosis and coronary artery disease. Philadelphia: Lippincott – Raven Publishers 1996: 639–656.

2. Jackson SP, Nesbitt, WS, Kulkarni S. Signaling events underlying thrombus formation. J Thrombos Haemostas 2003; 1: 1602–1612.

3. Ruggeri Z. The role of von Willebrand factor in trombus formation. Thromb Res 2007; 120: 5–9.

4. Yap CL, Anderson KE, Hughan SC et al. Essential role for phosphoinositide 3-kinase in shear dependent signaling between platelet glycoprotein Ib/V/IX and integrin αIIbβIII. Blood 2002; 99: 151–158.

5. Gibbons JM. Platelet adhesion signaling and the regulation of thrombus formation. J Cell Sci 2004; 117: 3415–3425.

6. Dalen JE. An apple a day or an aspirin a day. Arch Intern Med 1991; 151: 1066–1069.

7. McKee SA, Sane DC, Dellargyris EN. Aspirin resistance in cardiovascular diseases: A review of prevalence, mechanisms and clinical significance. Thromb Haemost 2002; 88: 711–715.

8. Samama MM, Elalamy I. Aspirine et hémostase. Rev Méd Interne 2000; 21: 27–34.

9. Awtry HA, Loscalzo J. Aspirin. Circulation 2000; 101: 1206–1218.

10. Hilmerová J, Filipovský J. Klinický význam aspirinové rezistence. Vnitř Lék 2004; 50: 462–469.

11. Vane JR, Bakhle YS, Botting RM. Cyklooxygenases 1 a 2. Annu Rev Pharmacol Toxicol 1998; 38: 97–120.

12. Patrono C, Coller B, Dalen JE et al. Platelet-Active Drugs. The relationship among dose, effectiveness and side effects. Chest 2001; 119: 39–63.

13. Gollapudi RR, Teirstein PS, Stevenson DD et al. Aspirin sensitivity. Implications for Patiens with coronary arterydisease. JAMA 2004; 292: 3017–3023.

14. Altman R, Luciardi HL, Muntaner J et al. The antitrombotic profile of Aspirin. Aspirin resistence, or simply failure? Thromb Haemost 2001; 2: 1.

15. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222–232.

16. Kahn ML, Nakanishi-Matsui M, Shapiro MJ et al. Protease‑activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879–887.

17. Gaspoz JM, Coxson PG, Goldman PA et al. Cost‑effectivenes of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346: 1800–1806.

18. Vojáček J. Inhibitory destičkových glykoproteinových receptorů typu IIb/IIIa. Remedia 2003; 13: 84–92.

19. Vojáček J, Malý M, Hraboš V et al. Hladina tkáňového faktoru, inhibitoru tkáňového faktoru a solubilního P-selektinu u nemocných s akutním koronárním syndromem. Cor Vasa 2002; 44: 148–151.